(Q43988038)

28 November 2017

Phase II trial of pegylated-liposomal doxorubicin (Doxil) in renal cell cancer (English)

1 reference

28 November 2017

phase II clinical trial

0 references

1 reference

Keith M Skubitz

1

1 reference

28 November 2017

1 February 2002

1 reference

Investigational New Drugs

28 November 2017

1 reference

28 November 2017

20

1 reference

28 November 2017

1

1 reference

28 November 2017

101-104

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1014428720551

28 November 2017

0 references

cites work

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

1 reference

12 December 2020

Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma

1 reference

12 December 2020

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

12 December 2020

Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes

1 reference

12 December 2020

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

1 reference

12 December 2020

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

1 reference

12 December 2020

Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes

1 reference

12 December 2020

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1014428720551

1 reference

PubMed ID

12003184

Dimensions Publication ID

28 November 2017

0 references

1 reference

PubMed ID

12003184